Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14176830 | 1.00 | BTK (0.59) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL12385790 | 1.00 | BTK (0.59) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL17915687 | 1.00 | BTK (0.59) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL14176836 | 1.00 | BTK (0.59) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL12384778 | 1.00 | BTK (0.59) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL15014612 | 1.00 | BTK (0.59) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL19676155 | 0.90 | BTK (0.69) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL12140717 | 0.90 | BTK (0.69) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL22688618 | 0.90 | BTK (0.69) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL16070789 | 0.90 | BTK (0.69) | BTKKDM1AMAOBCTSKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2022206939-A1 | HETEROCYCLIC COMPOUND SERVING AS FGFR INHIBITOR AND APPLICATION THEREOF | 海南耀臻生物医药科技有限公司 | 2022-10-06 | — | — | WO | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8394805-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110098282-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | US | disclosed |
| US-7777041-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
| US-7504511-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-20080153851-A1 | Cycloalkyl Piperidine Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | BTK 4806/4885KDM1A 3380/4885MAOB 127/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | BTK 690/4885KDM1A 1324/4885MAOB 749/4885 |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | PAH, ABAT, AADAT | BTK 2272/4885KDM1A 2770/4885MAOB 1230/4885 |
| US-20080153851-A1 | Cycloalkyl Piperidine Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | BTK 4599/4885KDM1A 1461/4885MAOB 1300/4885 |
| US-20110098282-A1 | NEW COMPOUNDS | BRDT, AURKAIP1, ABCG2 | BTK 3387/4885KDM1A 4175/4885MAOB 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.